Full-Time

Director – Clinical Data Management & Engineering

Clinical Data Management, Engineering

Posted on 8/5/2025

Karius

Karius

201-500 employees

Non-invasive liquid biopsy for infectious pathogens

Compensation Overview

$207.9k - $311.9k/yr

Remote in USA + 1 more

More locations: San Carlos, CA, USA

Remote

Hybrid position requiring some in-office presence.

Category
Data & Analytics (2)
,
Required Skills
Microsoft Azure
Python
Airflow
SAS
R
SQL
AWS
Google Cloud Platform
Requirements
  • Minimum Bachelor’s degree in a relevant field such as clinical informatics, data management, science, bioengineering, computer science, or life sciences and or life sciences and 8-10 years of experience in clinical data management, clinical informatics, data engineering, or related roles in biotech, diagnostics, or healthcare.
  • Master’s or PhD preferred. Masters requires 6 years of experience; PhD requires 4 years of experience in clinical data management, clinical informatics, data engineering, or related roles in biotech, diagnostics, or healthcare.
  • Proven knowledge of clinical data management process and clinical database systems.
  • Proven ability to design and implement clinical data infrastructure, with a focus on pipeline development, metadata management, and quality control processes.
  • Demonstrated experience with clinical systems and data types, including EDC, LIMS, ePRO, and associated regulatory frameworks (GCP, HIPAA, 21 CFR Part 11).
  • Proficiency in SQL and Python, with experience developing or managing ETL workflows using tools like Airflow, dbt, or equivalent.
  • Hands-on experience working in cloud environments (AWS, GCP, or Azure) for data engineering and storage solutions.
  • Familiarity with data governance, access control models, and SOP development in regulated settings.
  • Strong written and verbal communication skills, with ability to work across clinical, regulatory, and technical teams.
Responsibilities
  • Oversee, manage and optimize all aspects of the data management process for clinical trials and collaborations.
  • Develop and implement data management strategies and procedures to ensure accuracy, completeness, and timeliness of data.
  • Collaborate with cross-functional teams to define and implement data standards and processes.
  • Conduct regular quality checks and audits to ensure data integrity and compliance with regulatory requirements.
  • Identify and analyze data trends to improve data management processes and drive efficiency.
  • Manage and prioritize multiple projects, ensuring timely completion and delivery of high-quality data.
  • Design and operationalize clinical data workflows to support study operations, regulatory readiness, and long-term reusability of data.
  • Collaborate with the Engineering and Information Security & Compliance teams to define and enforce SOPs for clinical data ingestion, transformation, secure storage, access, and handoff, ensuring GCP and HIPAA compliance.
  • Manage data pipelines and integrations from EDC, LIMS, ePRO, and lab systems; ensure interoperability with downstream analysis environments (e.g., R, SAS).
  • Partner with Clinical Development, Computational Biology and Bioinformatics, Engineering, and Information Security & Compliance to ensure data is audit-ready and analysis-ready.
  • Act as a core stakeholder in the cross-functional data platform program, supporting ingestion and structuring of clinical, medical and real-world data as needed.
  • Support ad hoc data analyses and dashboard development for clinical program insights and cross-functional metrics tracking.
  • Document and catalog metadata, enabling structured data access for internal and external partners.
  • May provide operational oversight of Biostatistics team structure and resourcing depending on candidate experience and organizational evolution.
Desired Qualifications
  • Experience supporting or conducting clinical data analysis, including exploratory statistics or data visualization using tools like R, SAS, Tableau, or Python preferred.
  • Exposure to commercial or real-world data sources, such as CRM (e.g., Salesforce), diagnostic pipeline data, or customer reporting systems.
  • Knowledge of CDISC standards (SDTM, ADaM) and experience preparing datasets for regulatory submissions.
  • Experience in a fast-paced, cross-functional environment, preferably in a startup or high growth-stage biotech company.

Karius provides rapid, non-invasive infectious-disease diagnostics using the Karius Test, a liquid biopsy that detects over 1,000 pathogens from a single blood sample. The test analyzes microbial cell-free DNA circulating in the bloodstream, using advanced genomics and artificial intelligence to identify pathogens. It operates on real-time genomic data and a constantly updated reference database, enabling clinicians to diagnose infections without multiple invasive tests. Unlike traditional methods, Karius combines a broad pathogen panel with machine-learning analysis to deliver faster results and reduce unnecessary procedures. The company's goal is to help healthcare providers diagnose infections quickly, improve patient outcomes, and reduce healthcare costs by offering a faster, less invasive diagnostic option.

Company Size

201-500

Company Stage

Series C

Total Funding

$345M

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Designation expedites Karius Test approval for lung infections.
  • $100M Series C funding in May 2024 expands beyond 400 U.S. hospitals.
  • Test incorporated into 2023 Duke-ISCVID Criteria for infective endocarditis.

What critics are saying

  • Arcadia Biomed captures market share with faster plasma cfDNA test in 2025.
  • Illumina DRAGEN app enables in-house sequencing, eroding lab revenues by Q2 2025.
  • Day Zero Diagnostics displaces Karius in sepsis contracts through 2026.

What makes Karius unique

  • Karius Test detects over 1,000 pathogens via microbial cell-free DNA from single blood draw.
  • Proprietary AI analyzes genomic data in real-time for rapid infectious disease diagnosis.
  • CLIA-certified lab provides non-invasive liquid biopsy for immunocompromised patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Business Wire
May 16th, 2024
Karius Test® Receives Fda Breakthrough Device Designation To Aid In The Diagnosis Of Infectious Disease

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Karius®, Inc., a leader in genomic diagnostics for infectious diseases, announced today that the Karius Test® has been granted designation as a Breakthrough Device from The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA), for use in the diagnosis and management of immunocompromised patients with suspected lung infections including lower respiratory infection and pneumonia. “The Karius Test is commercially available nationwide as a laboratory developed test. We are seeking FDA marketing authorization of the Karius Test for lung infections in immunocompromised patients because improved diagnostic tests are urgently needed for these patients,” stated Brad Perkins, M.D., Chief Medical Officer of Karius. “As noted in the American Thoracic Society (ATS) Workshop Report for Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria,1 lung infections have high morbidity and mortality in immunocompromised patients, which is why advances in technologies like metagenomic sequencing used for the Karius Test are vital in improving the diagnosis and treatment of these patients.”. The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. This program is designed to expedite the development and review of these innovative medical devices

Forbes
May 8th, 2024
Innovationrx: Deepmind Unveils Its New Protein-Folding Ai Model Alphafold 3

InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. A protein folding prediction in response to a small molecule generated by AlphaFold 3.Isomorphic LabsToday, Deepmind announced the launch of AlphaFold 3, the next generation of its AI software for structural biology, which has enabled thousands of researchers to predict the complicated chemical interactions involved with proteins. One major difference in the new iteration of the program: instead of just predicting protein folding, it predicts the interactions of other biological molecules as well including DNA, RNA and small molecules. The company published the accuracy of its predictions in the journal Nature.In addition to the new capabilities–which even includes the ability to make predictions based on epigenetic changes to DNA–the company has also launched AlphaFold Server, a web service that enables researchers to generate biochemical models without having to install the system itself from open source code, as was the case with previous iterations. Something else new is that AlphaFold now works with diffusion models – which are popularly known for being used by AI systems that generate images from text prompts – in place of some of its previous structural models.“The response to AlphaFold 2 was more than I could have ever imagined in terms of the kind of creativity and what the research community has done with it,” Deepmind research director John Jumper said at a press briefing

CityBiz
May 3rd, 2024
Karius Secures $100M in Series C

Karius, Inc., a genomic diagnostics company, has raised $100 million in a Series C funding round co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare. The funds will be used to expand the reach of the Karius Test®, which detects over 1,000 pathogens from a single blood sample, beyond 400 U.S. hospitals. The company also added three new board members, including Alex Morgan from Khosla Ventures, Joep Muijrers from Gilde Healthcare, and Andrew Booth from 5AM Ventures.

RamaOnHealthcare
May 2nd, 2024
Karius Secures $100M to Expand Non-Invasive Pathogen Blood Test

Karius secures $100M to expand non-invasive pathogen blood Test.

Business Wire
May 2nd, 2024
Karius Secures $100M for Genomic Diagnostics Expansion

Karius, Inc. has raised $100M in Series C funding, co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, with participation from Seventure Partners and others. The funds will expand the reach of the Karius Test®, a genomic diagnostic test for infectious diseases, beyond 400 U.S. hospitals. The investment also supports research into microbial cell-free DNA technology. Additionally, Karius announced three new board members.

INACTIVE